Cargando…
Infliximab for Idiopathic Deep Cutaneous Vasculitis Refractory to Cyclophosphamide
Cutaneous vasculitis can be classified as primary or idiopathic; or secondary, when it presents as a manifestation of connective tissue diseases, infections, drug reactions or malignancies. Although most of the idiopathic cases are self-limited and responsive to supportive measures and nonsteroidal...
Autores principales: | , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3003994/ https://www.ncbi.nlm.nih.gov/pubmed/21188210 http://dx.doi.org/10.1155/2010/951850 |
_version_ | 1782193938030919680 |
---|---|
author | Schafranski, Marcelo Derbli Campanari, Giuliano Doretto |
author_facet | Schafranski, Marcelo Derbli Campanari, Giuliano Doretto |
author_sort | Schafranski, Marcelo Derbli |
collection | PubMed |
description | Cutaneous vasculitis can be classified as primary or idiopathic; or secondary, when it presents as a manifestation of connective tissue diseases, infections, drug reactions or malignancies. Although most of the idiopathic cases are self-limited and responsive to supportive measures and nonsteroidal anti-inflammatory drugs, potent immunosuppressants are sometimes required for the management of the refractory situations. Here we describe a case of a 32-year-old Caucasian female patient with history of idiopathic cutaneous deep vasculitis unresponsive to methotrexate, dapsone, and cyclophosphamide who was effectively treated with infliximab. |
format | Text |
id | pubmed-3003994 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-30039942010-12-23 Infliximab for Idiopathic Deep Cutaneous Vasculitis Refractory to Cyclophosphamide Schafranski, Marcelo Derbli Campanari, Giuliano Doretto Int J Vasc Med Case Report Cutaneous vasculitis can be classified as primary or idiopathic; or secondary, when it presents as a manifestation of connective tissue diseases, infections, drug reactions or malignancies. Although most of the idiopathic cases are self-limited and responsive to supportive measures and nonsteroidal anti-inflammatory drugs, potent immunosuppressants are sometimes required for the management of the refractory situations. Here we describe a case of a 32-year-old Caucasian female patient with history of idiopathic cutaneous deep vasculitis unresponsive to methotrexate, dapsone, and cyclophosphamide who was effectively treated with infliximab. Hindawi Publishing Corporation 2010 2010-06-27 /pmc/articles/PMC3003994/ /pubmed/21188210 http://dx.doi.org/10.1155/2010/951850 Text en Copyright © 2010 M. D. Schafranski and G. D. Campanari. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Schafranski, Marcelo Derbli Campanari, Giuliano Doretto Infliximab for Idiopathic Deep Cutaneous Vasculitis Refractory to Cyclophosphamide |
title | Infliximab for Idiopathic Deep Cutaneous Vasculitis Refractory to Cyclophosphamide |
title_full | Infliximab for Idiopathic Deep Cutaneous Vasculitis Refractory to Cyclophosphamide |
title_fullStr | Infliximab for Idiopathic Deep Cutaneous Vasculitis Refractory to Cyclophosphamide |
title_full_unstemmed | Infliximab for Idiopathic Deep Cutaneous Vasculitis Refractory to Cyclophosphamide |
title_short | Infliximab for Idiopathic Deep Cutaneous Vasculitis Refractory to Cyclophosphamide |
title_sort | infliximab for idiopathic deep cutaneous vasculitis refractory to cyclophosphamide |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3003994/ https://www.ncbi.nlm.nih.gov/pubmed/21188210 http://dx.doi.org/10.1155/2010/951850 |
work_keys_str_mv | AT schafranskimarceloderbli infliximabforidiopathicdeepcutaneousvasculitisrefractorytocyclophosphamide AT campanarigiulianodoretto infliximabforidiopathicdeepcutaneousvasculitisrefractorytocyclophosphamide |